TBPH
Theravance Biopharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$854.78M
P/E Ratio
8.06
EPS
$2.06
Beta
0.17
52W High
$21.03
52W Low
$8.16
50-Day MA
$17.06
200-Day MA
$15.42
Dividend Yield
—
Profit Margin
98.50%
Forward P/E
7.49
PEG Ratio
-0.05
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe, and Asia. The company is headquartered in George Town, the Cayman Islands.
Fundamentals
| Revenue (TTM) | $107.46M |
| Gross Profit (TTM) | $70.05M |
| EBITDA | $-1.98M |
| Operating Margin | 43.60% |
| Return on Equity | 44.90% |
| Return on Assets | -0.54% |
| Revenue/Share (TTM) | $2.14 |
| Book Value | $5.81 |
| Price-to-Book | 2.78 |
| Price-to-Sales (TTM) | 7.95 |
| EV/Revenue | 5.14 |
| EV/EBITDA | 4.11 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 144.70% |
| Shares Outstanding | $51.49M |
| Float | $24.13M |
| % Insiders | 3.80% |
| % Institutions | 98.02% |
Historical Volatility
HV 10-Day
37.71%
HV 20-Day
30.36%
HV 30-Day
96.07%
HV 60-Day
72.59%
HV Rank
98.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($17.20 target)
3
Buy4
HoldData last updated: 4/9/2026